Join the NCI Director for the ASCO Virtual Education Program’s Opening Session Tomorrow

NCI at ASCO FRIDAY, AUGUST 7 The American Society of Clinical Oncology Virtual Education Program starts tomorrow. We encourage you to register to access scheduled broadcast sessions, along with on-demand videos, slides, and exhibits.

Tune in Tomorrow: Join the NCI Director for the Education Program’s Opening Session Broadcasting Saturday, August 8, at 8:30 a.m. EDT. NCI Director, Norman E. Sharpless, MD, will participate in a panel discussion with ASCO leaders Cliff Hudis, MD, and Skip Burris, MD. Dr. Sharpless will explain the flexibilities NCI granted to clinical trials during the COVID-19 pandemic and highlight how the lessons learned will support future cancer research and effective patient care. Watch NCI’s Cancer Research Experts Present During Scheduled Broadcasts Chasing Sarcoma in the Blood: Circulating Tumor Cells and DNA │ August 9, 9:00 a.m. EDT  NCI Presenter: Tony Dickherber, PhD NCI program director Dr. Tony Dickherber will present “The Emerging Liquid Biopsy Technology Landscape." Dr. Dickherber will discuss the commercial landscape for available platforms and approaches, persistent technical challenges that hamper their adoption, and emerging technologies that NCI has supported to address those challenges. In addition, he will discuss the important role clinician-scientists can and should play in accelerating the incorporation of liquid biopsies into clinical trials with sarcoma patients. Immunotherapy Beyond Checkpoints in Melanoma │ August 10, 10:00 a.m. EDT NCI Presenter: Stephanie L. Goff, MD Dr. Stephanie Goff, Associate Research Physician in NCI’s Surgery Branch, will present “Killer T’s: the History and Future of Cell Therapy.” Dr. Goff’s presentation will discuss cell-based immunotherapy for the treatment of metastatic melanoma, starting from the earliest studies of lymphokine-activated killer cells in 1985 to the latest studies of tumor infiltrating lymphocytes (TIL) for clinical treatment and neoantigen exploration for future T-cell receptor (TCR) gene-engineered cells. Note: All scheduled broadcast sessions will be available to watch on demand two hours after the close of the broadcast.